SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma

被引:482
|
作者
Chow, Pierce K. H. [1 ,2 ]
Gandhi, Mihir [2 ,3 ]
Tan, Say-Beng [3 ,4 ]
Khin, Maung Win [8 ]
Khasbazar, Ariunaa [9 ]
Ong, Janus [10 ,11 ]
Choo, Su Pin [1 ]
Cheow, Peng Chung [5 ]
Chotipanich, Chanisa [15 ]
Lim, Kieron [6 ]
Lesmana, Laurentius A. [16 ,17 ]
Manuaba, Tjakra W. [18 ]
Yoong, Boon Koon [19 ]
Raj, Aloysius [20 ]
Law, Chiong Soon [21 ]
Cua, Ian H. Y. [12 ]
Lobo, Rolley R. [13 ]
Teh, Catherine S. C. [14 ]
Kim, Yun Hwan [22 ]
Jong, Yun Won [23 ]
Han, Ho-Seong [24 ]
Bae, Si-Hyun [25 ]
Yoon, Hyun-Ki [26 ]
Lee, Rheun-Chuan [27 ]
Hung, Chien-Fu [29 ]
Peng, Cheng-Yuan [30 ]
Liang, Po-Chin [28 ]
Bartlett, Adam [31 ]
Kok, Kenneth Y. Y. [32 ]
Thng, Choon-Hua [1 ]
Low, Albert Su-Chong [5 ]
Goh, Anthony S. W. [5 ]
Tay, Kiang Hiong [5 ]
Lo, Richard H. G. [5 ]
Goh, Brian K. P. [5 ]
Ng, David C. E. [5 ]
Lekurwale, Ganesh [3 ]
Liew, Wei Ming [3 ]
Gebski, Val [33 ]
Mak, Kenneth S. W. [7 ]
Soo, Khee Chee [1 ]
机构
[1] Natl Canc Ctr Singapore, Singapore, Singapore
[2] Duke NUS Med Sch, Singapore, Singapore
[3] Singapore Clin Res Inst, Singapore, Singapore
[4] SingHealth, Singapore, Singapore
[5] Singapore Gen Hosp, Singapore, Singapore
[6] Natl Univ Singapore Hosp, Singapore, Singapore
[7] Khoo Teck Puat Hosp, Singapore, Singapore
[8] Yangon GI & Liver Ctr, Yangon, Myanmar
[9] Natl Canc Ctr Mongolia, Ulaanbaatar, Mongolia
[10] Med City, Pasig, Philippines
[11] Univ Philippines Manila, Manila, Philippines
[12] St Lukes Med Ctr Global City, Taguig, Philippines
[13] Davao Doctors Hosp, Davao, Philippines
[14] Makati Med Ctr, Makati, Philippines
[15] Chulabhorn Hosp, Bangkok, Thailand
[16] Cipto Mangunkusumo Hosp, Jakarta, Indonesia
[17] Univ Indonesia, Jakarta, Indonesia
[18] Sanglah Hosp, Denpasar, Indonesia
[19] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia
[20] Penang Adventist Hosp, George Town, Malaysia
[21] Sarawak Gen Hosp, Kuching, Malaysia
[22] Korea Univ, Anam Hosp, Seoul, South Korea
[23] Severance Hosp, Seoul, South Korea
[24] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
[25] Seoul St Marys Hosp, Seoul, South Korea
[26] Asan Med Ctr, Seoul, South Korea
[27] Taipei Vet Gen Hosp, Taipei, Taiwan
[28] Natl Taiwan Univ Hosp, Taipei, Taiwan
[29] Chang Gung Mem Hosp, Linkou Branch, Taoyuan, Taiwan
[30] China Med Univ Hosp, Taichung, Taiwan
[31] Auckland City Hosp, Auckland, New Zealand
[32] Brunei Canc Ctr, Jerudong, Brunei
[33] Univ Sydney, Natl Hlth & Med Res Council Clin Trials Ctr, Camperdown, NSW, Australia
关键词
Y-90; MICROSPHERES; RADIOEMBOLIZATION; RADIOTHERAPY; MANAGEMENT; PATTERNS; SURVIVAL; OUTCOMES; SARAH;
D O I
10.1200/JCO.2017.76.0892
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeSelective internal radiation therapy or radioembolization (RE) shows efficacy in unresectable hepatocellular carcinoma (HCC) limited to the liver. This study compared the safety and efficacy of RE and sorafenib in patients with locally advanced HCC.Patients and MethodsSIRveNIB (selective internal radiation therapy v sorafenib), an open-label, investigator-initiated, phase III trial, compared yttrium-90 (Y-90) resin microspheres RE with sorafenib 800 mg/d in patients with locally advanced HCC in a two-tailed study designed for superiority/detriment. Patients were randomly assigned 1:1 and stratified by center and presence of portal vein thrombosis. Primary end point was overall survival (OS). Efficacy analyses were performed in the intention-to-treat population and safety analyses in the treated population.ResultsA total of 360 patients were randomly assigned (RE, 182; sorafenib, 178) from 11 countries in the Asia-Pacific region. In the RE and sorafenib groups, 28.6% and 9.0%, respectively, failed to receive assigned therapy without significant cross-over to either group. Median OS was 8.8 and 10.0 months with RE and sorafenib, respectively (hazard ratio, 1.1; 95% CI, 0.9 to 1.4; P = .36). A total of 1,468 treatment-emergent adverse events (AEs) were reported (RE, 437; sorafenib, 1,031). Significantly fewer patients in the RE than sorafenib group had grade 3 AEs (36 of 130 [27.7%]) v 82 of 162 [50.6%]; P < .001). The most common grade 3 AEs were ascites (five of 130 [3.8%] v four of 162 [2.5%] patients), abdominal pain (three [2.3%] v two [1.2%] patients), anemia (zero v four [2.5%] patients), and radiation hepatitis (two [1.5%] v zero [0%] patients). Fewer patients in the RE group (27 of 130 [20.8%]) than in the sorafenib group (57 of 162 [35.2%]) had serious AEs.ConclusionIn patients with locally advanced HCC, OS did not differ significantly between RE and sorafenib. The improved toxicity profile of RE may inform treatment choice in selected patients.
引用
收藏
页码:1913 / +
页数:12
相关论文
共 50 条
  • [41] Selective internal radiation therapy in treatment of hepatocellular carcinoma: new concepts of personalization
    Abraham, Jella-Andrea
    Yeghiazaryan, Kristina
    Golubnitschaja, Olga
    PERSONALIZED MEDICINE, 2016, 13 (04) : 347 - 360
  • [42] Selective internal radiation therapy with SIR-Spheres in hepatocellular carcinoma and cholangiocarcinoma
    Wang, Eric A.
    Broadwell, Scott R.
    Bellavia, Ross J.
    Stein, Jeff P.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (02) : 266 - 278
  • [43] Downstaging locally advanced hepatocellular carcinoma with selective internal radiation therapy.
    Hoang, Marjorie
    Chow, Pierce K. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 536 - 536
  • [44] Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): collective results from the phase III sorafenib HCC assessment randomized protocol (SHARP) and Asia-Pacific (AP) trials
    Llovet, J.
    Cheng, A.
    Qin, S.
    Shan, M.
    Nadel, A.
    Burock, K.
    Forner, A.
    Zou, J.
    Bruix, J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 367 - 367
  • [45] EORTC quality-of-life assesment in an Asia-Pacific hepatocellular carcinoma trial
    戴美珠
    周嘉豪
    林静芳
    苏启智
    ActaPharmacologicaSinica, 1998, (S1) : 84 - 84
  • [46] EORTC quality-of-life assessment in an Asia-Pacific hepatocellular carcinoma trial
    Tai, BC
    Chow, P
    Lim, CH
    Johnson, P
    Soo, KC
    ACTA PHARMACOLOGICA SINICA, 1998, 19 : 81 - 81
  • [47] Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
    Omata, Masao
    Cheng, Ann-Lii
    Kokudo, Norihiro
    Kudo, Masatoshi
    Lee, Jeong Min
    Jia, Jidong
    Tateishi, Ryosuke
    Han, Kwang-Hyub
    Chawla, Yoghesh K.
    Shiina, Shuichiro
    Jafri, Wasim
    Alcantara Payawal, Diana
    Ohki, Takamasa
    Ogasawara, Sadahisa
    Chen, Pei-Jer
    Lesmana, Cosmas Rinaldi A.
    Lesmana, Laurentius A.
    Gani, Rino A.
    Obi, Shuntaro
    Dokmeci, A. Kadir
    Sarin, Shiv Kumar
    HEPATOLOGY INTERNATIONAL, 2017, 11 (04) : 317 - 370
  • [48] Impact of prior surgical resection with curative intent on the efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): Subset analysis of the Asia-Pacific (AP) study
    Yang, T.
    Qin, S.
    Tak, W.
    Yu, S.
    Tsao, C.
    Kim, J.
    Burock, K.
    Zou, J.
    Voliotis, D.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    Chen, Zhendong
    Tsao, Chao-Jung
    Qin, Shukui
    Kim, Jun Suk
    Luo, Rongcheng
    Feng, Jifeng
    Ye, Shenglong
    Yang, Tsai-Sheng
    Xu, Jianming
    Sun, Yan
    Liang, Houjie
    Liu, Jiwei
    Wang, Jiejun
    Tak, Won Young
    Pan, Hongming
    Burock, Karin
    Zou, Jessie
    Voliotis, Dimitris
    Guan, Zhongzhen
    LANCET ONCOLOGY, 2009, 10 (01): : 25 - 34
  • [50] Phase 2 Study of Combined Sorafenib and Radiation Therapy in Patients With Advanced Hepatocellular Carcinoma
    Chen, Shang-Wen
    Lin, Li-Ching
    Kuo, Yu-Cheng
    Liang, Ji-An
    Kuo, Chia-Chun
    Chiou, Jeng-Fong
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (05): : 1041 - 1047